Postsurgical Salvage Radiosurgery for Nonfunctioning Pituitary Adenomas Touching/Compressing the Optic Chiasm: Median 13-Year Postirradiation Imaging Follow-up Results.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 10 2019
Historique:
received: 22 03 2018
accepted: 11 07 2018
pubmed: 1 9 2018
medline: 31 3 2020
entrez: 1 9 2018
Statut: ppublish

Résumé

There is little information on long-term outcomes after salvage treatment by either surgery or stereotactic radiosurgery (SRS) for patients with recurrent/residual nonfunctioning pituitary adenomas (NFPAs). To reappraise the efficacy and safety of SRS for patients with NFPAs touching/compressing the optic apparatus (OA). We studied 27 patients (14 females, 13 males; mean age: 61 [range, 19-85] yr) who underwent SRS between 1998 and 2008 for NFPAs with such condition. The median tumor volume was 4.9 (range, 1.8-50.8) cc. To avoid excess irradiation to the OA, the lower part of the tumor was covered with a 50% or a 60% isodose gradient, ie 49% to 98% (mean, 84%; median, 88%) of the entire tumor received the selected doses. Median doses at the tumor periphery/OA were 7.6/11.0 (interquartile range [IQR], 5.8-9.1/10.1-11.8) Gy. Seven patients (26%) were confirmed to be deceased due to unrelated diseases at a median post-SRS period of 149 (IQR, 83-158) mo. Follow-up magnetic resonance imaging (MRI) showed tumor growth in 2 patients (7%) at the 11th and 134th post-SRS month; the former underwent surgery and the other SRS. Excluding these 2 patients, the latest follow-up MRI examinations, performed 13 to 238 (median: 168, IQR: 120-180) mo after SRS, showed no size changes in 5 (19%) and shrinkage in 20 (74%) patients. Cumulative incidences of tumor growth control were 96.3% and 91.8% at the 120th and 180th post-SRS month. None of our patients developed subjective symptoms suggesting SRS-induced optic neuropathy or endocrinological impairment. In patients with NFPAs touching/compressing the OA, SRS achieves good long-term results.

Sections du résumé

BACKGROUND
There is little information on long-term outcomes after salvage treatment by either surgery or stereotactic radiosurgery (SRS) for patients with recurrent/residual nonfunctioning pituitary adenomas (NFPAs).
OBJECTIVE
To reappraise the efficacy and safety of SRS for patients with NFPAs touching/compressing the optic apparatus (OA).
METHODS
We studied 27 patients (14 females, 13 males; mean age: 61 [range, 19-85] yr) who underwent SRS between 1998 and 2008 for NFPAs with such condition. The median tumor volume was 4.9 (range, 1.8-50.8) cc. To avoid excess irradiation to the OA, the lower part of the tumor was covered with a 50% or a 60% isodose gradient, ie 49% to 98% (mean, 84%; median, 88%) of the entire tumor received the selected doses. Median doses at the tumor periphery/OA were 7.6/11.0 (interquartile range [IQR], 5.8-9.1/10.1-11.8) Gy.
RESULTS
Seven patients (26%) were confirmed to be deceased due to unrelated diseases at a median post-SRS period of 149 (IQR, 83-158) mo. Follow-up magnetic resonance imaging (MRI) showed tumor growth in 2 patients (7%) at the 11th and 134th post-SRS month; the former underwent surgery and the other SRS. Excluding these 2 patients, the latest follow-up MRI examinations, performed 13 to 238 (median: 168, IQR: 120-180) mo after SRS, showed no size changes in 5 (19%) and shrinkage in 20 (74%) patients. Cumulative incidences of tumor growth control were 96.3% and 91.8% at the 120th and 180th post-SRS month. None of our patients developed subjective symptoms suggesting SRS-induced optic neuropathy or endocrinological impairment.
CONCLUSION
In patients with NFPAs touching/compressing the OA, SRS achieves good long-term results.

Identifiants

pubmed: 30169702
pii: 5087980
doi: 10.1093/neuros/nyy357
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

476-485

Informations de copyright

Copyright © 2018 by the Congress of Neurological Surgeons.

Auteurs

Masaaki Yamamoto (M)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.
Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

Hitoshi Aiyama (H)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Takao Koiso (T)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Shinya Watanabe (S)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.
Tsukuba Clinical Research and Development Organization, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Takuya Kawabe (T)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.
Department of Neurosurgery, Rakusai Shimizu Hospital, Kyoto, Japan.

Yasunori Sato (Y)

Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.

Yoshinori Higuchi (Y)

Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.

Bierta E Barfod (BE)

Katsuta Hospital Mito GammaHouse, Hitachi-naka, Ibaraki, Japan.

Hidetoshi Kasuya (H)

Department of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH